Efficacy Comparison of Mepolizumab and Benralizumab in Patients with Severe Eosinophilic Asthma: A Retrospective Cohort Analysis
By
Wei-Chun Huang
Yi-Luen Shen
Wen-Chien Cheng
Chien-Wen Huang
Chia-Hung Chen
Chih- Yen Tu
Wu-Huei Hsu
February 10, 2026
Clinical Scorecard: Efficacy Comparison of Mepolizumab and Benralizumab in Patients with Severe Eosinophilic Asthma: A Retrospective Cohort Analysis
At a Glance
Category Detail
Condition Severe Eosinophilic Asthma Key Mechanisms Mepolizumab neutralizes IL-5; Benralizumab targets IL-5 receptor α and induces eosinophil apoptosis. Target Population Patients aged ≥ 20 years with severe eosinophilic asthma and a history of acute exacerbations. Care Setting Tertiary referral centers in Taiwan.
Key Highlights
Both mepolizumab and benralizumab are effective in reducing acute exacerbations. Mepolizumab binds to circulating IL-5; benralizumab induces eosinophil apoptosis. Real-world evidence shows variable efficacy between the two agents. Patients were followed for 12 months post-initiation of therapy. Inclusion criteria emphasized severe asthma with eosinophilia. Guideline-Based Recommendations
Diagnosis
Clinical diagnosis based on symptoms and spirometric features. Baseline eosinophil count ≥ 300 cells/μL required. Management
Initiation of biologic therapy for patients with step 5 asthma. Regular follow-up and adjustments to medications as needed. Monitoring & Follow-up
Regular assessments of pulmonary function, ACT scores, and eosinophil counts. Risks
Exclusion of patients with cancer, autoimmune diseases, or concurrent biologic therapy. Patient & Prescribing Data
Patients initiating therapy for the first time with either mepolizumab or benralizumab.
Patients underwent structured healthcare case management to optimize outcomes.
Clinical Best Practices
Conduct regular follow-ups every 1 month post-initiation of therapy. Utilize the Asthma Control Test (ACT) for monitoring symptom control. Ensure adherence to GINA guidelines for severe asthma management. Related Resources & Content
